Cat. #161914
SK-MEL-1 Cell Line
Cat. #: 161914
Availability: 8-10 weeks
Tissue: Skin
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Herbert F. Oettgen
Institute: Memorial Sloan-Kettering Cancer Center (MSK)
Primary Citation: Oettgen et al. 1968. Journal of the National Cancer Institute. 41: 827-843. PMID: 4879578.
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: SK-MEL-1 Cell Line
- Cancer: Skin cancer
- Cancers detailed: Melanoma
- Gender: Male
- Tissue: Skin
- Donor: 29-year-old, White male patient with melanoma.
- Morphology: Spherical
- Growth properties: Clusters in suspension
- Products or characteristics of interest: Electron microscopy revealed pigment granules relating both to synthesis and to phagocytosis. Antibody to this line was detected in 63% of patients with malignant melanoma and in 10% of patients with other diseases.
- Description: SK-MEL-1 are melanocytes established from patient-derived tumour samples. This cell line expresses mutant B-Raf (V600E) and wildtype N-Ras and were isolated from the skin of a 29-year-old, White male patient with melanoma.
- Application: 3D cell culture
- Biosafety level: 1
- Recommended controls: -
Target Details
- Target: Antigen expression: Blood Type A; Rh+
Applications
- Application: 3D cell culture
Handling
- Growth medium: EMEM suplemented with 10% FBS.
- Temperature: 37° C
- Shipping conditions: Dry Ice
- Storage medium: Complete growth medium, 95%; DMSO, 5%
- Storage conditions: Vapor phase of liquid nitrogen. Storage at -70° C will result in loss of viability.
- Subculture routine: Cultures can be maintained by addition or replacement of fresh medium. Establish new cultures at 1 x 105 cells/mL and maintain at 2 x 105 cells/mL. Medium Renewal: 2 to 3 times per week
- Characterisation tests: -
- Str profiling: Amelogenin: X,Y;CSF1PO: 12,13;D13S317: 11;D16S539: 11,12;D5S818: 12,13;D7S820: 12;TH01: 6;TPOX: 11;vWA: 16,17;D3S1358: 14,16;D21S11: 29,32.2;D18S51: 13,16;Penta_E: 7,21;Penta_D: 11,13;D8S1179: 13,16;FGA: 18,20;D19S433: 15,16.2;D2S1338: 19,23
Related Tools
- Related tools: -
References
- Xing et al. 2012. Oncogene. 31(4):446-457. PMID: 21725359.
- Fogh et al. 1977. Journal of the National Cancer Institute. 59: 221-226. PMID: 327080.
- Oettgen et al. 1968. Journal of the National Cancer Institute. 41: 827-843. PMID: 4879578.
